PROCEPT BioRobotics Corporation (PRCT) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $22.11 (-4.72%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 27, 2026 | Richard Newitter | Truist Financial | $30.00 | +35.7% |
| Feb 26, 2026 | Nathan Treybeck | Wells Fargo | $34.00 | +53.8% |
| Dec 18, 2025 | Richard Newitter | Truist Financial | $47.00 | +112.6% |
| Dec 12, 2025 | Danielle Antalffy | UBS | $62.00 | +180.4% |
| Dec 2, 2025 | Patrick Wood | Morgan Stanley | $51.00 | +130.7% |
| Nov 5, 2025 | Matt O'Brien | Piper Sandler | $50.00 | +126.1% |
| Nov 5, 2025 | Mike Kratky | Leerink Partners | $55.00 | +148.8% |
| Sep 2, 2025 | Suraj Kalia | Oppenheimer | $60.00 | +171.4% |
| Dec 2, 2024 | Patrick Wood | Morgan Stanley | $105.00 | +374.9% |
| Oct 29, 2024 | Richard Newitter | Truist Financial | $105.00 | +374.9% |
| Sep 3, 2024 | Richard Newitter | Truist Financial | $95.00 | +329.7% |
| Jul 16, 2024 | Richard Newitter | Truist Financial | $79.00 | +257.3% |
| May 6, 2024 | Matt O'Brien | Piper Sandler | $75.00 | +239.2% |
| May 2, 2024 | Richard Newitter | Truist Financial | $72.00 | +225.6% |
| Sep 2, 2022 | Nathan Treybeck | Wells Fargo | $49.00 | +121.6% |
Top Analysts Covering PRCT
PRCT vs Sector & Market
| Metric | PRCT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.33 | 2.24 | 2.41 |
| Analyst Count | 9 | 8 | 19 |
| Target Upside | +24.7% | +11475.0% | +17.1% |
| P/E Ratio | -13.43 | 4.04 | 31.98 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $384M | $396M | $420M | 9 |
| 2027-03-31 | $97M | $104M | $109M | 4 |
| 2027-06-30 | $111M | $118M | $125M | 6 |
| 2027-09-30 | $119M | $127M | $133M | 4 |
| 2027-12-31 | $135M | $144M | $151M | 7 |
| 2028-03-31 | $118M | $126M | $133M | 3 |
| 2028-06-30 | $137M | $146M | $154M | 5 |
| 2028-09-30 | $141M | $150M | $158M | 3 |
| 2028-12-31 | $177M | $188M | $198M | 6 |
| 2029-12-31 | $629M | $661M | $692M | 3 |
| 2030-12-31 | $701M | $737M | $772M | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.64 | $-1.54 | $-1.48 | 9 |
| 2027-03-31 | $-0.40 | $-0.37 | $-0.34 | 3 |
| 2027-06-30 | $-0.29 | $-0.27 | $-0.25 | 2 |
| 2027-09-30 | $-0.21 | $-0.20 | $-0.18 | 2 |
| 2027-12-31 | $-0.07 | $-0.07 | $-0.06 | 2 |
| 2028-03-31 | $-0.59 | $-0.55 | $-0.51 | 3 |
| 2028-06-30 | $-0.32 | $-0.30 | $-0.27 | 6 |
| 2028-09-30 | $-0.25 | $-0.23 | $-0.21 | 5 |
| 2028-12-31 | $0.05 | $0.05 | $0.05 | 5 |
| 2029-12-31 | $-0.34 | $-0.33 | $-0.30 | 1 |
| 2030-12-31 | $0.38 | $0.41 | $0.43 | 1 |
Frequently Asked Questions
What is the analyst consensus for PRCT?
The consensus among 9 analysts covering PROCEPT BioRobotics Corporation (PRCT) is Buy with an average price target of $42.40.
What is the highest price target for PRCT?
The highest price target for PRCT is $105.00, set by Patrick Wood at Morgan Stanley on 2024-12-02.
What is the lowest price target for PRCT?
The lowest price target for PRCT is $30.00, set by Richard Newitter at Truist Financial on 2026-02-27.
How many analysts cover PRCT?
9 analysts have issued ratings for PROCEPT BioRobotics Corporation in the past 12 months.
Is PRCT a buy or sell right now?
Based on 9 analyst ratings, PRCT has a consensus rating of Buy (2.33/5) with a +24.7% upside to the consensus target of $42.40.
What are the earnings estimates for PRCT?
Analysts estimate PRCT will report EPS of $-1.54 for the period ending 2026-12-31, with revenue estimated at $396M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.